quinazolines has been researched along with Glial Cell Tumors in 140 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.43) | 18.2507 |
| 2000's | 53 (37.86) | 29.6817 |
| 2010's | 81 (57.86) | 24.3611 |
| 2020's | 4 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, Q; Ma, S; Mao, Y; Yin, W; Yu, Q; Zhang, K; Zhao, R | 1 |
| Alfred Yung, WK; Ding, J; Gao, F; Khan, S; Koul, D; Li, X; Lozano, G; Sen, S; Wasylishen, AR; Zhang, C; Zhao, Y | 1 |
| Deng, Z; Du, Z; Li, X; Tao, Z; Wang, H; Zhou, Y | 1 |
| Guo, J; Huang, Q; Liu, L; Wang, X; Wang, Y; Xi, H | 1 |
| Breunig, JJ; Chan, SL; Chen, Y; Ching, J; Ding, LW; Doan, N; Dutra-Clarke, M; Hazawa, M; Jiang, YY; Koeffler, HP; Kovalik, JP; Lin, DC; Madan, V; Mayakonda, A; Müschen, M; Said, JW; Savinoff, SE; Tyner, JW; Watkins, A; Xu, L; Yang, H; Yong, WH | 1 |
| Edwards, A; Glass, JO; Li, Y; Patay, Z; Reddick, WE; Svolos, P; Sykes, A | 1 |
| Chen, YC; Chien, CC; Chiu, WT; Liu, KH; Wu, WS | 1 |
| Chen, X; He, Q; Li, H; Li, M; Liu, Y; Long, Y; Lu, L; Qiu, Y; Tang, J; Wang, X; Yu, Q; Zhang, Z | 1 |
| Broniscer, A; Merchant, TE; Nguyen, R; Onar-Thomas, A; Patay, Z; Pierson, CR | 1 |
| Alamón, C; Cabral, P; Cabrera, M; Cerecetto, H; Couto, M; García, MF; Merlino, A; Teixidor, F; Viñas, C | 1 |
| Amrutkar, SM; Banerjee, UC; Cholia, RP; Joshi, G; Kalra, S; Kaur, G; Kumar, R; Mantha, AK | 1 |
| Gao, H; Hu, C; Liu, R; Qin, L; Su, D; Wang, G; Yang, C; Yang, X; Yang, Y; Yu, M; Zhou, Y | 1 |
| Gupta, P; Mukhopadhyay, CK; Pandey, HS; Seth, P; Singh, P | 1 |
| Broniscer, A; Hillenbrand, CM; Kocak, M; Loeffler, RB; Sedlacik, J; Winchell, A | 1 |
| Inoue, H; Ishikawa, T; Kajimoto, Y; Kuroiwa, T; Miyatake, S; Sun, W | 1 |
| Broniscer, A; Gajjar, A; Kaste, SC; Kaufman, RA | 1 |
| Baker, JN; Baker, SD; Broniscer, A; Chin, TK; Davidoff, AM; Gajjar, A; Huang, J; Kaste, SC; Merchant, TE; Onar-Thomas, A; Pai Panandiker, AS; Panetta, JC; Stewart, CF; Wetmore, C | 1 |
| Boult, JK; Bradley, DP; Robinson, SP; Terkelsen, J; Walker-Samuel, S | 1 |
| Blakeley, JO; Brem, H; Grossman, R; Khan, U; Kim, E; Pathak, AP; Rudek, MA; Tyler, B; Zadnik, P | 1 |
| Blaney, SM; Boyett, JM; Fouladi, M; Gajjar, A; Geyer, JR; Gilbertson, RJ; Goldman, S; Kun, LE; Onar-Thomas, A; Packer, RJ; Schaiquevich, P; Stewart, CF | 1 |
| Agar, JN; Agar, NY; Alberta, J; Davis, E; Easterling, ML; Ebling, MC; Ide, JL; Kellersberger, KA; Kesari, S; Liu, X; Marchionni, MA; Norton, I; Santagata, S; Sauvageot, CM; Stiles, CD; Stuart, DD; Wang, LY | 1 |
| Gillespie, GY; Green, SC; Lobo, MR; Pike, MM; Schabel, MC; Woltjer, RL | 1 |
| Becker, J; Bicknell, R; Bikfalvi, A; Exertier, P; Franco, M; Godard, V; Hagedorn, M; Herbert, J; Javerzat, S; Nivelles, O; Ormenese, S; Pineau, R; Platonova, N; Pujol, N; Wang, B; Wilting, J; Winandy, M | 1 |
| Cai, L; Gao, S; Pu, P; Sun, J; Yang, W; Zhang, A; Zhang, K | 1 |
| Cao, S; Chen, C; Chen, J; Gao, H; Jiang, X; Wang, Y; Wei, Y | 1 |
| Cao, S; Chen, C; Chen, J; Gao, H; Jiang, X; Xi, Z; Zhang, Q | 1 |
| Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Drappatz, J; Gilbert, MR; Groves, MD; Kuhn, JG; Lamborn, KR; Lieberman, FS; Ligon, AH; Ligon, KL; Mehta, MP; Norden, AD; Prados, MD; Robins, HI; Santagata, S; Wen, PY; Wright, JJ; Yung, WK | 1 |
| Chen, Y; Feng, Z; He, Q; Liang, C; Meng, L; Shu, M; Yang, D; Yu, K; Zhao, H | 1 |
| Feng, D; Hu, Q; Li, H; Ma, H; Su, Y; Tao, H; Wang, X; Zhang, C | 1 |
| Chang, CY; Chen, CJ; Chen, WY; Huang, HY; Kuan, YH; Li, JR; Ou, YC; Pan, PH; Wu, CC | 1 |
| Kaminska, B; Maleszewska, M; Steranka, A | 1 |
| Gillespie, GY; Lobo, MR; Pike, MM; Wang, X; Woltjer, RL | 1 |
| Canoll, P; Chen, S; Guo, B; Horner, JW; Klingler, S; Paik, JH; Vaseva, AV; Wang, YA; Yan, H; Yao, J; Ying, H; Zhang, L; Zheng, H | 1 |
| Chu, L; Kan, P; Li, X; Wang, Q; Wang, Z; Xin, X; Yang, P; Zhu, Y | 1 |
| Cao, Q; Fu, SY; Li, Y; Wang, FY; Wang, LH; Wang, NN; Wang, YT; Wu, CF; Yang, JY | 1 |
| Cima, MJ; Hochberg, FH; Ong, Q | 1 |
| Chang, CY; Chen, CJ; Chen, WY; Kuan, YH; Li, JR; Ou, YC; Wang, WY; Wu, CC | 1 |
| Gillespie, GY; Grafe, MR; Kukino, A; Lobo, MR; Pike, MM; Schabel, MC; Springer, CS; Tran, H; Woltjer, RL | 1 |
| Hartel, I; Rieger, J; Ronellenfitsch, M; Steinbach, JP; Wanka, C; Wolking, S | 1 |
| Guo, AS; Huang, YQ; Lin, RS; Ma, XD | 1 |
| Ferlini, C; Mozzetti, S; Riccardi, A; Riccardi, R; Servidei, T | 1 |
| Bradley, DP; Jürgensmeier, JM; Kilburn, L; Lacey, T; Mills, J; Odedra, R; Scott, M; Tessier, JJ; Wedge, SR | 1 |
| Ali-Osman, F; Cao, X; Lo, HW; Zhu, H | 1 |
| Fu, Z; Liu, YL; Mu, DB; Song, B; Song, XR; Teng, XP; Wang, H; Wang, XW; Wei, L; Yang, GR; Yu, JM; Zhao, SQ | 1 |
| David, K; Drappatz, J; Gerard, M; Kesari, S; McNamara, MB; Muzikansky, A; Norden, AD; Phan, P; Ross, A; Wen, PY | 1 |
| Bajetto, A; Barbieri, F; Capra, MC; Corte, G; Daga, A; Favoni, RE; Florio, T; Gatti, M; Griffero, F; Lo Casto, M; Marubbi, D; Melotti, A; Pattarozzi, A; Porcile, C; Spaziante, R; Zona, G | 1 |
| Baker, SJ; Broniscer, A; Ellison, DW; Endersby, R; Gajjar, A; Kocak, M; Laningham, FH; Merchant, TE; Morris, EB; Schaiquevich, P; Stewart, CF | 1 |
| Ali-Osman, F; Bigner, D; Buolamwini, J; Friedman, H; Haystead, T; Okamura, T; Singh, S | 1 |
| de Boüard, S; Guillamo, JS; Leuraud, P; Marie, Y; Marteau, L; Parienti, JJ; Peschanski, M; Poupon, MF; Raymond, E; Valable, S | 1 |
| Broniscer, A; Christiansen, SR; Panetta, JC; Stewart, CF | 1 |
| Argyriou, AA; Dimitrakopoulos, F; Dimitropoulos, K; Giannopoulou, E; Kalofonos, HP; Koutras, AK | 1 |
| Addo-Yobo, SO; Jane, EP; Pollack, IF; Premkumar, DR | 1 |
| D'Elia, A; Formichella, AI; Frati, A; Salvati, M | 1 |
| Jeibmann, A; Klämbt, C; Paulus, W; Witte, HT | 1 |
| Al-Sarraj, S; Bax, DA; Ellison, DW; Gaspar, N; Hargrave, D; Jones, C; Little, SE; Marshall, L; Pearson, AD; Perryman, L; Regairaz, M; Reis, RM; Reis-Filho, JS; Sharp, SY; Stávale, JN; Vassal, G; Viana-Pereira, M; Vuononvirta, R; Workman, P | 1 |
| Abrey, LE; Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Abrey, LE; Aldape, KA; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Boockvar, JA; Edgar, MA; Karampelas, I; Luther, N; Souliopoulos, EP; Souweidane, MM | 1 |
| Bradshaw, TD; Laughton, CA; Madhusudan, S; Stevens, MF; Zhang, J | 1 |
| Cheng, SY; Chiou, SH; Feng, H; Hu, B; Lieberman, FS; Liu, KW; Ma, HI; Sarkaria, JN; Schornack, PA; Sengar, RS; Wiener, EC; Yiin, JJ | 1 |
| Calabrese, C; Carcaboso, AM; Elmeliegy, MA; Juel, SJ; Shen, J; Stewart, CF; Tracey, L; Waters, CM; Zhang, ZM | 1 |
| Jean-Claude, BJ; Rachid, Z; Watt, HL | 1 |
| Stupp, R; Tabatabai, G | 1 |
| Banerjee, A; Blaney, SM; Boyett, JM; Broniscer, A; Douglas, JG; Geyer, JR; Gilbertson, RJ; Gururangan, S; Kieran, MW; Kocak, M; Kun, LE; Packer, RJ; Phillips, P; Stewart, CF | 1 |
| Desjardins, A; Friedman, HS; Gururangan, S; Hamilton, M; Herndon, JE; Marcello, J; Mathe, A; McLendon, RE; Norfleet, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Antti, H; Bergenheim, AT; Henriksson, R; Johansson, M; Sandström, M; Wibom, C | 1 |
| Baker, JN; Broniscer, A; Chin, TK; Davidoff, AM; Gajjar, A; Gilbertson, RJ; Kaste, SC; Kocak, M; Leung, W; Merchant, TE; Onar-Thomas, A; Pai Panandiker, AS; Panandiker, AP; Rowland, C; Stewart, CF; Tagen, M | 1 |
| Aerts, I; Andreiuolo, F; Chatelut, E; Frappaz, D; Gentet, JC; Geoerger, B; Hargrave, D; Jaspan, T; Le Deley, MC; Leblond, P; Méresse, V; Morland, B; Ndiaye, A; Paoletti, X; Riccardi, R; Saint-Rose, C; Thomas, F; Varlet, P; Vassal, G | 1 |
| Chen, C; Damek, D; Fields, EC; Gaspar, LE; Kavanagh, BD; Lillehei, K; Liu, AK; Waziri, A | 1 |
| Boyett, JM; Geyer, R; Haas-Kogan, D; Kieran, MW; Kun, L; Ng, S; Pollack, IF; Poussaint, TY; Prabhu, SP; Vajapeyam, S | 1 |
| Banerjee, A; Boyett, JM; Broniscer, A; Douglas, JG; Geyer, JR; Kocak, M; Kun, LE; Pollack, IF; Poussaint, TY; Stewart, CF | 1 |
| Boyett, JM; Cha, S; Geyer, R; Haas-Kogan, D; Kocak, M; Kun, LE; Packer, RI; Patay, Z; Pollack, IF; Poussaint, TY; Robertson, RL; Vajapeyam, S; Vezina, G; Zimmerman, R | 1 |
| Claes, A; Hamans, BC; Heerschap, A; Jeuken, JW; Leenders, WP; Navis, AC; Wesseling, P | 1 |
| Bota, DA; Gong, X; Linskey, ME; Schwartz, PH | 1 |
| Catana, C; Farrar, CT; Jain, RK; Kamoun, WS; Kim, YR; Kwon, SJ; Ley, CD; Rosen, BR; Sorensen, AG | 1 |
| Asano, K; Ohkuma, H | 1 |
| Andersen, B; Dicker, AP; Lawrence, RY; Liu, Y; Wachsberger, PR; Xia, X | 1 |
| Halatsch, ME; Karpel-Massler, G; Wirtz, CR | 1 |
| Chang, CY; Chen, CJ; Shen, CC; Su, HL | 1 |
| Cheng, Y; Huber-Keener, KJ; Keihack, H; Liao, J; Liu, X; Ren, X; Rubin, E; Yan, L; Yang, JM; Zhang, L; Zhang, Y; Zhou, L | 1 |
| Chen, J; Fan, Y; Li, Q; Xing, X; Yu, Q; Zhan, H; Zhan, L; Zhang, Y | 1 |
| Amberger-Murphy, V; Clarke, C; Clynes, M; Doolan, P; Farrell, M; Howley, R; Kinsella, P; Madden, SF | 1 |
| Baker, LC; Boult, JK; Burrell, JS; Halliday, J; Jamin, Y; Robinson, SP; Ryan, AJ; Walker-Samuel, S; Waterton, JC | 1 |
| Diaz, RJ; Golbourn, B; Rutka, JT; Shekarforoush, M; Smith, CA | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; McLendon, RE; McSherry, F; Peters, KB; Reardon, DA; Rich, JN; Sampson, JH; Sathornsumetee, S; Threatt, S; Vredenburgh, JJ; Zhang, S | 1 |
| Constantini, S; Kane, R; MacDonald, TJ; McCowage, G; Packer, RJ; Rood, B; Yalon, M | 1 |
| Gao, Q; Kang, KB; Ty, A; Wong, MC; Wong, YL; Zhu, C | 1 |
| Lemmon, MA; Park, JH | 1 |
| Barkovich, KJ; Blair, JA; Fan, QW; Garske, AL; Hariono, S; Nicolaides, T; Shokat, KM; Weiss, WA; Zhang, J | 1 |
| Brennan, CW; Campos, C; Chang, SM; Chheda, MG; Cloughesy, TF; Dang, J; DeAngelis, LM; Drappatz, J; Fine, HA; Gilbert, MR; Grommes, C; Heguy, A; Horvath, S; Iwanami, A; Kubek, S; Kuga, D; Kuhn, JG; Lamborn, KR; Lassman, AB; Liau, LM; Lieberman, F; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nghiemphu, PL; Oldrini, B; Pedraza, A; Prados, MD; Reardon, DA; Robins, HI; Rohle, D; Tao, H; Vivanco, I; Wen, PY; Wu, N; Yannuzzi, N; Yong, WH; Yung, WK; Zhu, S | 1 |
| Arango, V; Bruce, JN; Canoll, P; Kassir, SA; Kumar, JS; Majo, VJ; Mann, JJ; Polavarapu, H; Prabhakaran, J; Simpson, NR; Underwood, MD | 1 |
| Codacci-Pisanelli, G; Della Rocca, C; Frati, L; Gulino, A; Lo Russo, G; Miele, E; Miscusi, M; Papa, A; Petrozza, V; Spinelli, GP; Tomao, S | 1 |
| Cloughesy, T; Green, RM; Lai, A; Nghiemphu, PL; Reardon, DA | 1 |
| Jin, X; Joshi, K; Kim, H; Kim, SH; Nakano, I; Nam, DH; Sohn, YW; Yin, J | 1 |
| Cao, S; Gao, H; Jiang, X; Pang, Z; Xi, Z; Yang, Z; Zhang, S | 1 |
| Fine, HA; Iwamoto, FM; Kreisl, TN; McNeill, KA; Shih, J; Sul, J | 1 |
| Bobos, M; Chrisafi, S; Fountzilas, G; Karavasilis, V; Kotoula, V; Lambaki, S; Pentheroudakis, G; Televantou, D | 1 |
| Albanese, C; Alzani, R; Amboldi, N; Brasca, M; Ciomei, M; Degrassi, A; Festuccia, C; Fiorentini, F; Galvani, A; Gravina, G; Mercurio, C; Pastori, W; Pesenti, E | 1 |
| Barriuso, J; Curtis, CM; Dar, MM; de Bono, J; Groves, MD; Ma, B; McLendon, RE; Mikkelsen, T; Nabors, L; Raizer, J; Reardon, DA; Rosenfeld, S; Suttle, AB; Wen, PY | 1 |
| Campos-Martín, Y; García-Claver, A; Lorente, M; Meléndez, B; Mollejo, M; Mur, P; Velasco, G | 1 |
| Almqvist, Y; Carlsson, J; Sundberg, AL; Tolmachev, V | 1 |
| Chang, CM; Li, B; McKenna, WG; Shu, HK; Yuan, M | 1 |
| Burgess, AW; Johns, TG; Jungbluth, AA; Luwor, RB; Murone, C; Nice, EC; Old, LJ; Perera, RM; Scott, AM; Stockert, E; Vitali, AA; Walker, F; Weinstock, J | 1 |
| Fan, QW; Goldenberg, DD; Shokat, KM; Specht, KM; Weiss, WA; Zhang, C | 1 |
| Klumpp, A; Steinbach, JP; Weller, M; Wolburg, H | 1 |
| De Tribolet, N; Diserens, AC; Godard, S; Hamou, MF; Hegi, ME; Kobayashi, H; Lachat, Y; Nozaki, M | 1 |
| Andersson, U; Bergenheim, AT; Bergh, A; Henriksson, R; Johansson, M; Sandström, M | 1 |
| Eisenmann, C; Klumpp, A; Steinbach, JP; Weller, M | 1 |
| Bryant, JA; Charles, AC; Cloughesy, TF; Finn, RS; Slamon, DJ | 1 |
| Carpentier, AF | 1 |
| Hoang-Xuan, K; Sanson, M; Thillet, J | 1 |
| Carpentier, AF; Delattre, JY; Hoang-Xuan, K; Marie, Y; Omuro, AM; Sanson, M; Thillet, J | 1 |
| Cappuzzo, F | 1 |
| Arvold, ND; Baumber, R; Berger, MS; Eberhard, DA; Haas-Kogan, DA; Jelluma, N; Kapadia, A; Lamborn, KR; Malec, M; Prados, MD; Stokoe, D; Tihan, T | 1 |
| Kurisu, K; Okamura, T | 1 |
| Abrey, LE; Chang, S; Cowell, JK; DeAngelis, LM; Gilbert, MR; Grefe, CN; Holland, EC; Kuhn, JG; Lamborn, K; Lassman, AB; Lieberman, FS; Nowak, NJ; Pao, W; Prados, M; Raizer, JJ; Razier, JR; Rossi, MR; Shih, AH; Wen, P; Wilson, R; Yung, WA | 1 |
| Bigner, DD; Dimery, I; Friedman, HS; Graner, MW; Kaipainen, A; Keir, ST; Kieran, MW; Laforme, A; McLendon, RE; Rasheed, BK; Reardon, DA; Rich, JN; Ryan, AJ; Sathornsumetee, S; Wang, L; Wheeler, C | 1 |
| Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D | 1 |
| Bigner, DD; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Lyons, P; McLendon, RE; Ochs, JS; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Sathornsumetee, S; Smith, RP; Swaisland, AJ; Tourt-Uhlig, S; Vredenburgh, JJ | 1 |
| Arnold, B; Pollack, IF; Premkumar, DR | 1 |
| Berger, MS; Keles, GE | 1 |
| Stummer, W | 1 |
| Abourbeh, G; Ben Daniel, R; Dissoki, S; Jacobson, O; Laki, D; Levitzki, A; Litchi, A; Mishani, E | 1 |
| Blatt, V; Brandes, AA; Cavallo, G; Crinò, L; Franceschi, E; Grosso, D; Lonardi, S; Magrini, E; Pession, A; Scopece, L; Tallini, G; Tosoni, A; Urbini, B | 1 |
| Chopp, M; Hong, X; Jiang, F; Kalkanis, SN; Katakowski, M; Yang, H; Zhang, X; Zhang, ZG; Zheng, X | 1 |
| Battastini, AM; Bavaresco, L; Bernardi, A; Delgado-Cañedo, A; Jacques-Silva, MC; Lenz, G; Wink, MR | 1 |
| Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK | 1 |
| Cheng, CK; Fan, QW; Hackett, CS; Knight, ZA; Nicolaides, TP; Shokat, KM; Weiss, WA | 1 |
| Andersson, U; Behnam-Motlagh, P; Johansson, D; Johansson, M; Malmer, B | 1 |
| Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Lillehei, K; Schwer, AL; Stuhr, K | 1 |
| Claes, A; Gambarota, G; Hamans, B; Heerschap, A; Leenders, W; Maass, C; van Tellingen, O; Wesseling, P | 1 |
| Dasmahapatra, B; Demma, MJ; Naumann, U; Roth, P; Weinmann, L; Weller, M; Wischhusen, J | 1 |
| Bergenheim, AT; Bergström, P; Henriksson, R; Johansson, M; Sandström, M | 1 |
| Devanz, P; Gaspar, N; Geoerger, B; Grill, J; Lacroix, L; Lecluse, Y; Morizet, J; Opolon, P; Valent, A; Vassal, G | 1 |
| Bertalanffy, A; Dieckmann, K; Dietrich, W; Gelpi, E; Hainfellner, JA; Marosi, C; Prayer, D; Preusser, M; Rottenfusser, A; Widhalm, G | 1 |
| Caday, CG; Cavenee, WK; Han, Y; Huang, HJ; Nanda, A | 1 |
| Cavenee, WK; Huang, HJ; Lin, H; Nagane, M | 1 |
| Cavenee, WK; Huang, HJ; Steinbach, JP; Supra, P; Weller, M | 1 |
| El-Obeid, A; Hesselager, G; Nistér, M; Westermark, B | 1 |
| Cairncross, JG; Eisenhauer, EA; Kerr, IG; MacCormick, RE; Macdonald, DR; Moore, MJ; Rathbone, MP; Sawka, CA | 1 |
8 review(s) available for quinazolines and Glial Cell Tumors
| Article | Year |
|---|---|
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Quinazolines; Temozolomide | 2009 |
[Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Glioma; Humans; Microcirculation; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Snake Venoms; Vascular Endothelial Growth Factor A | 2010 |
Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug Combinations; Drug Synergism; Erlotinib Hydrochloride; Glioma; Humans; Models, Biological; Neoplasm Grading; Quinazolines | 2011 |
Chemotherapy and target therapy in the management of adult high- grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central Nervous System Neoplasms; Cetuximab; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Nitrosourea Compounds; Organophosphorus Compounds; Promoter Regions, Genetic; Quinazolines; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2012 |
Neuro-oncology: the growing role of chemotherapy in glioma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Resistance, Neoplasm; Gefitinib; Glioblastoma; Glioma; Humans; Meta-Analysis as Topic; Nitrosourea Compounds; Oligodendroglioma; Paraneoplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Temozolomide | 2005 |
Molecular changes in gliomas.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Central Nervous System Neoplasms; Epidermal Growth Factor; Gefitinib; Glioma; Humans; Neovascularization, Pathologic; Quinazolines | 2004 |
[Molecular targeted therapy for malignant brain tumors].
Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Piperidines; Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2005 |
Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications.
Topics: Apoptosis; Drug Resistance, Neoplasm; ErbB Receptors; Glioma; Humans; Mutation; Quinazolines; Signal Transduction; Tyrphostins | 2001 |
31 trial(s) available for quinazolines and Glial Cell Tumors
| Article | Year |
|---|---|
Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation.
Topics: Antineoplastic Agents; Brain Stem; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dexamethasone; Diffusion Tensor Imaging; Disease Progression; Disease-Free Survival; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Piperidines; Prospective Studies; Quinazolines; Steroids; Vascular Endothelial Growth Factor A; White Matter | 2017 |
Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Brain; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Female; Glioma; Humans; Leukoencephalopathies; Magnetic Resonance Imaging; Male; Piperidines; Quinazolines; Radiotherapy, Conformal; Stroke; Tumor Burden | 2017 |
MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents; Blood Volume; Brain Stem Neoplasms; Child; Child, Preschool; Cohort Studies; Disease Progression; Echo-Planar Imaging; Female; Follow-Up Studies; Glioma; Humans; Image Enhancement; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Neoadjuvant Therapy; Neuroimaging; Piperidines; Prospective Studies; Quinazolines; Radiotherapy, Conformal; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Treatment Outcome | 2013 |
Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Brain Stem Neoplasms; Child; Child, Preschool; Dasatinib; Female; Follow-Up Studies; Glioma; Humans; Infant; Knee Joint; Magnetic Resonance Imaging; Male; Osteonecrosis; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Radiography; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Child, Preschool; Dasatinib; Female; Glioma; Humans; Male; Piperidines; Pyrimidines; Quinazolines; Thiazoles; Treatment Outcome | 2013 |
A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
Topics: Adolescent; Antineoplastic Agents; Blotting, Western; Central Nervous System Neoplasms; Child; Child, Preschool; Ependymoma; ErbB Receptors; Female; Glioma; Humans; Infant; Lapatinib; Male; Medulloblastoma; Neoplasm Grading; Quinazolines; Treatment Outcome; Young Adult | 2013 |
A pilot study on EGFR-targeted molecular imaging of PET/CT With 11C-PD153035 in human gliomas.
Topics: Adult; Aged; Biological Transport; Carbon Radioisotopes; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Male; Middle Aged; Multimodal Imaging; Pilot Projects; Positron-Emission Tomography; Quinazolines; Tomography, X-Ray Computed | 2014 |
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Survival Rate; Tissue Distribution; Young Adult | 2014 |
Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
Topics: Adolescent; Adult; Anticonvulsants; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2009 |
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Male; Maximum Tolerated Dose; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Young Adult | 2010 |
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Tissue Distribution | 2010 |
A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Glioma; Humans; Male; Maximum Tolerated Dose; Quinazolines; Supratentorial Neoplasms; Young Adult | 2010 |
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate; Tissue Distribution | 2010 |
Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Piperidines; Quinazolines; Radiotherapy, Adjuvant; Treatment Outcome; Young Adult | 2010 |
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.
Topics: Adolescent; Adult; Brain Stem Neoplasms; Child; Child, Preschool; Erlotinib Hydrochloride; Female; Glioma; Humans; Infant; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Therapies, Investigational; Tissue Distribution; Treatment Outcome; Young Adult | 2011 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Dexamethasone; Drug Administration Schedule; Female; Glioma; Glucocorticoids; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide; Tumor Burden; Vincristine; Young Adult | 2012 |
A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Female; Gefitinib; Glioma; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Quinazolines; Radiotherapy Dosage; Survival Rate; Tissue Distribution; Treatment Outcome; Young Adult | 2011 |
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dasatinib; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Quinazolines; Thiazoles; Tissue Distribution; Young Adult | 2012 |
A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Feasibility Studies; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Sirolimus; Survival Rate; Tissue Distribution | 2012 |
A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Young Adult | 2012 |
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Quinazolines; Temozolomide | 2013 |
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Topics: Adult; Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Glioma; Humans; Indazoles; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Recurrence; Sulfonamides | 2013 |
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Mutation; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Supratentorial Neoplasms; Temozolomide; Tumor Suppressor Proteins | 2005 |
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Clinical Trials as Topic; Cluster Analysis; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Genome; Glioma; Humans; Lung Neoplasms; Models, Biological; Mutation; Nucleic Acid Hybridization; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Time Factors | 2005 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Temozolomide; Treatment Outcome | 2006 |
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Glioma; Humans; Male; Middle Aged; Quinazolines; Recurrence; Sirolimus; Treatment Outcome | 2006 |
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligodendroglioma; Quinazolines; Survival Rate; Treatment Outcome | 2007 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Edema; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Gefitinib; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Quinazolines; Temozolomide | 2008 |
A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dose Fractionation, Radiation; Female; Gefitinib; Glioma; Humans; Male; Maximum Tolerated Dose; Mental Status Schedule; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines; Radiosurgery; Treatment Outcome | 2008 |
Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.
Topics: Adult; Aged; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Secondary Prevention | 2008 |
101 other study(ies) available for quinazolines and Glial Cell Tumors
| Article | Year |
|---|---|
AZD3759 inhibits glioma through the blockade of the epidermal growth factor receptor and Janus kinase pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Janus Kinases; Male; Mice; Piperazines; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma.
Topics: Animals; DNA; DNA-Activated Protein Kinase; ErbB Receptors; Glioblastoma; Glioma; Mice; Pyridazines; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2022 |
Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzodioxoles; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Injections, Intraventricular; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Quinazolines; Receptor, Notch1; Signal Transduction; SOXB1 Transcription Factors; src-Family Kinases; Stereotaxic Techniques; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
[Evodiamine Promotes Apoptosis of Glioma SHG-44 Cells and Its Mechanism].
Topics: Apoptosis; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation; Glioma; Humans; Quinazolines | 2020 |
BCL6 promotes glioma and serves as a therapeutic target.
Topics: Animals; Axl Receptor Tyrosine Kinase; Brain Neoplasms; Cell Line, Tumor; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; MAP Kinase Kinase Kinases; Mice, Mutant Strains; Molecular Targeted Therapy; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-6; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |
Evodiamine Prevents Glioma Growth, Induces Glioblastoma Cell Apoptosis and Cell Cycle Arrest through JNK Activation.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blood-Brain Barrier; Cell Cycle Checkpoints; Cell Survival; Cell Transformation, Neoplastic; Evodia; Glioblastoma; Glioma; Humans; JNK Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Tumor Cells, Cultured | 2017 |
Enhanced glioma therapy by synergistic inhibition of autophagy and tyrosine kinase activity.
Topics: Animals; Antineoplastic Agents; Autophagy; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Endothelial Cells; Glioma; Hydroxychloroquine; Integrin alphaVbeta3; Liposomes; Male; Mice; Piperidines; Protein-Tyrosine Kinases; Quinazolines | 2018 |
Discovery of Potent EGFR Inhibitors through the Incorporation of a 3D-Aromatic-Boron-Rich-Cluster into the 4-Anilinoquinazoline Scaffold: Potential Drugs for Glioma Treatment.
Topics: Aniline Compounds; Blood-Brain Barrier; Boron; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Glioma; Humans; Protein Kinase Inhibitors; Quinazolines | 2018 |
Anticancer activity of dihydropyrazolo[1,5-c]quinazolines against rat C6 glioma cells via inhibition of topoisomerase II.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; G1 Phase Cell Cycle Checkpoints; Glioma; Humans; Models, Molecular; Quinazolines; Rats; Reactive Oxygen Species; Topoisomerase II Inhibitors | 2018 |
D-T7 Peptide-Modified PEGylated Bilirubin Nanoparticles Loaded with Cediranib and Paclitaxel for Antiangiogenesis and Chemotherapy of Glioma.
Topics: Animals; Bilirubin; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Collagen Type IV; Drug Carriers; Glioma; Humans; Male; Mice; Nanoparticles; Paclitaxel; Peptide Fragments; Quinazolines | 2019 |
Phosphoinositide-3-kinase inhibition elevates ferritin level resulting depletion of labile iron pool and blocking of glioma cell proliferation.
Topics: Adenine; Animals; Brain Neoplasms; Cell Proliferation; Cells, Cultured; Chromones; Down-Regulation; Ferritins; Glioma; Humans; Iron; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Pyrimidinones; Quinazolines; Rats; Thiazolidinediones; Up-Regulation | 2019 |
Gefitinib enhances the efficacy of photodynamic therapy using 5-aminolevulinic acid in malignant brain tumor cells.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Gefitinib; Glioma; Humans; Photochemotherapy; Photosensitizing Agents; Quinazolines; Treatment Outcome | 2013 |
A multi-parametric imaging investigation of the response of C6 glioma xenografts to MLN0518 (tandutinib) treatment.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Contrast Media; Diagnostic Imaging; Diffusion Magnetic Resonance Imaging; Female; Glioma; Humans; Mice; Mice, Nude; Piperazines; Quinazolines; Rats; Xenograft Model Antitumor Assays | 2013 |
Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Cerebral Ventricle Neoplasms; Cerebral Ventricles; Dacarbazine; Drug Synergism; Extracellular Fluid; Glioma; Humans; Male; Microdialysis; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Nude; Receptors, Vascular Endothelial Growth Factor; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging.
Topics: Animals; Antineoplastic Agents; Biomarkers; Blood-Brain Barrier; Brain Neoplasms; Disease Models, Animal; Erlotinib Hydrochloride; Glioma; Heme; Heterografts; Humans; Mice; Molecular Imaging; Neovascularization, Pathologic; Optical Imaging; Permeability; Pharmaceutical Preparations; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2013 |
Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Capillary Permeability; Drug Synergism; Female; Glioma; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Quinacrine; Quinazolines; Tumor Burden; Tumor Cells, Cultured | 2013 |
Impaired angiogenesis and tumor development by inhibition of the mitotic kinesin Eg5.
Topics: Animals; Cell Growth Processes; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Gene Expression; Glioma; Human Umbilical Vein Endothelial Cells; Humans; Kinesins; Mice; Mitosis; Neovascularization, Pathologic; Quinazolines; Recombinant Proteins; Thiones; Vascular Endothelial Growth Factor A; Zebrafish | 2013 |
Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug.
Topics: Animals; Area Under Curve; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Endocytosis; G2 Phase Cell Cycle Checkpoints; Glioma; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Osteonectin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Solubility; Survival Rate; Time Factors | 2014 |
In vivo behavior and safety of lapatinib-incorporated lipid nanoparticles.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Glioma; Injections, Intravenous; Lapatinib; Lethal Dose 50; Lipids; Male; Mice, Inbred ICR; Nanoparticles; Organ Specificity; Particle Size; Quinazolines; Rats, Sprague-Dawley; Solubility; Surface Properties; Tablets; Tissue Distribution | 2014 |
A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Glioma; Humans; Inhibitory Concentration 50; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-met; Pyridazines; Pyridones; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Stomach Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.
Topics: AC133 Antigen; Antigens, CD; Azepines; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioma; Glycoproteins; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Histones; Humans; Lysine; Methylation; Neoplastic Stem Cells; Peptides; Promoter Regions, Genetic; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Transfection | 2014 |
Autophagy contributes to gefitinib-induced glioma cell growth inhibition.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apoptosis Regulatory Proteins; Autophagy; Cell Line, Tumor; Gefitinib; Glioma; Growth Inhibitors; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Ribonucleotides; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
The effects of selected inhibitors of histone modifying enzyme on C6 glioma cells.
Topics: Acetylation; Adenosine; Animals; Azepines; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Epigenesis, Genetic; Glioma; Histones; Hydroxamic Acids; Piperazines; Quinazolines; Rats; Valproic Acid | 2014 |
Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic vacuole accumulation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Enzyme Activation; Glioma; Mice; Proto-Oncogene Proteins c-akt; Quinacrine; Quinazolines; Vacuoles | 2014 |
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.
Topics: Animals; Brain Neoplasms; Crizotinib; Cyclin-Dependent Kinase Inhibitor p16; Doxycycline; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imidazoles; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Phosphorylation; Protein Processing, Post-Translational; PTEN Phosphohydrolase; Pyrazoles; Pyridines; Quinazolines; Quinolines; Tumor Cells, Cultured | 2015 |
The Effects and Molecular Mechanisms of MiR-106a in Multidrug Resistance Reversal in Human Glioma U87/DDP and U251/G Cell Lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroRNAs; Quinazolines | 2015 |
Copper improves the anti-angiogenic activity of disulfiram through the EGFR/Src/VEGF pathway in gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Disulfiram; Drug Synergism; ErbB Receptors; Gefitinib; Glioma; Gluconates; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Quinazolines; Signal Transduction; src-Family Kinases; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
Depot delivery of dexamethasone and cediranib for the treatment of brain tumor associated edema in an intracranial rat glioma model.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Brain Neoplasms; Cells, Cultured; Dexamethasone; Drug Delivery Systems; Drug Liberation; Edema; Female; Glioma; Human Umbilical Vein Endothelial Cells; Protein Kinase Inhibitors; Quinazolines; Rats, Inbred F344 | 2015 |
Valproic acid sensitizes human glioma cells to gefitinib-induced autophagy.
Topics: Adenylate Kinase; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Gefitinib; Glioma; Humans; Oxidative Stress; Quinazolines; Reactive Oxygen Species; Valproic Acid | 2015 |
Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Glioma; Mice; Quinazolines; Semicarbazones | 2015 |
Activation of AMP-activated kinase modulates sensitivity of glioma cells against epidermal growth factor receptor inhibition.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Glioma; Glucose; Glycolysis; Humans; Imatinib Mesylate; K562 Cells; Phosphorylation; Pyrones; Quinazolines; Thiophenes | 2016 |
Mechanism of G9a inhibitor BIX‑01294 acting on U251 glioma cells.
Topics: Adult; Apoptosis; Azepines; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Glioma; Histocompatibility Antigens; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Male; Middle Aged; Neoplasm Proteins; Quinazolines | 2016 |
Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Cyclin D1; DNA, Complementary; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunoblotting; Immunoprecipitation; Neoplasms; Ovarian Neoplasms; Phosphorylation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Repressor Proteins; RNA, Small Interfering; Sequence Analysis, DNA; Signal Transduction | 2008 |
Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Colorectal Neoplasms; Contrast Media; Disease Models, Animal; Dose-Response Relationship, Drug; Gadolinium DTPA; Glioma; Humans; Magnetic Resonance Imaging; Quinazolines; Rats; Rats, Nude; Treatment Outcome | 2009 |
Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; DNA Damage; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Inhibitory Concentration 50; Janus Kinase 2; Mice; Quinazolines; STAT3 Transcription Factor | 2008 |
[Molecular imaging of epidermal growth factor receptor in glioma-bearing rats].
Topics: Animals; Brain Neoplasms; Carbon Radioisotopes; Cell Line, Tumor; ErbB Receptors; Gastrointestinal Tract; Glioma; Liver; Male; Neoplasm Transplantation; Positron-Emission Tomography; Quinazolines; Rats; Rats, Wistar; Tissue Distribution; Tomography, X-Ray Computed | 2008 |
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carbazoles; Clinical Trials as Topic; Disease-Free Survival; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis | 2009 |
Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.
Topics: Aged; Animals; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Microfilament Proteins; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Tensins; Time Factors; Tumor Cells, Cultured | 2009 |
Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell-Free System; Cisplatin; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Glioma; Glutathione S-Transferase pi; Humans; Lapatinib; Mice; Mice, Nude; Models, Molecular; Molecular Sequence Data; Neoplasm Transplantation; Phosphorylation; Protein Conformation; Quinazolines; Recombinant Proteins; RNA, Small Interfering; Signal Transduction; Static Electricity; Transplantation, Heterologous; Tyrosine | 2009 |
Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Brain; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Glioma; Humans; Mice; Mice, Nude; Mutation; Neoplasm Invasiveness; Neovascularization, Pathologic; Organ Culture Techniques; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; RNA Interference; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2009 |
Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature.
Topics: Biological Availability; Brain Neoplasms; Child; Combined Modality Therapy; Cystic Fibrosis; Erlotinib Hydrochloride; Exocrine Pancreatic Insufficiency; Female; Glioma; Humans; Malabsorption Syndromes; Pancrelipase; Protein Kinase Inhibitors; Quinazolines | 2009 |
An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glioma; Humans; Indoles; Lapatinib; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrroles; Quinazolines; Sunitinib | 2010 |
Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells.
Topics: Apoptosis; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Glioma; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Vorinostat | 2009 |
Modeling glioma growth and invasion in Drosophila melanogaster.
Topics: Animals; Brain Neoplasms; Drosophila melanogaster; ErbB Receptors; Eye; Gefitinib; Glioma; Humans; Immunoenzyme Techniques; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured | 2009 |
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
Topics: Adolescent; Blotting, Western; Cell Proliferation; Child; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Prognosis; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Deletion; Tumor Cells, Cultured | 2009 |
Interstitial infusion of erlotinib in the rodent brain.
Topics: Animals; Body Weight; Brain; Brain Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Microinjections; Neostriatum; Quinazolines; Rats; Rats, Nude | 2009 |
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Glioblastoma; Glioma; Humans; Nitrogen Mustard Compounds; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotide Array Sequence Analysis; Quinazolines; Temozolomide; Tumor Stem Cell Assay | 2010 |
ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
Topics: Animals; bcl-X Protein; Brain; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Glioma; Humans; Magnetic Resonance Imaging; Mice; Mutant Proteins; Neovascularization, Pathologic; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; STAT3 Transcription Factor; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Gefitinib; Glioma; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Models, Biological; Mutation; Octreotide; Phosphorylation; Quinazolines; Signal Transduction; Temozolomide; Time Factors; Transfection | 2010 |
Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Administration Schedule; ErbB Receptors; Glioma; Multivariate Analysis; Nerve Tissue Proteins; Piperidines; Protein Kinase Inhibitors; Proteomics; Quinazolines; Rats; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Time Factors | 2010 |
DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium.
Topics: Adolescent; Anisotropy; Antineoplastic Agents; Brain Stem; Brain Stem Neoplasms; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Diffusion Tensor Imaging; Gefitinib; Glioma; Humans; Image Interpretation, Computer-Assisted; Male; Nerve Fibers, Myelinated; Quinazolines; Quinolones; Radiotherapy | 2011 |
MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Diffusion; Female; Gefitinib; Glioma; Humans; Magnetic Resonance Imaging; Male; Quinazolines; Quinolones; Radiotherapy Dosage; Research Design; Survival Rate; Treatment Outcome | 2011 |
Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Glioma; Humans; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Pyrroles; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glioma; Humans; Neoplastic Stem Cells; Neural Stem Cells; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Temozolomide | 2011 |
Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model.
Topics: Animals; Biomarkers, Tumor; Capillary Permeability; Cell Line, Tumor; Cell Proliferation; Diffusion; Disease Models, Animal; Extracellular Space; Glioma; Humans; Magnetic Resonance Imaging; Mice; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2011 |
Epithelial growth factor receptor tyrosine kinase inhibitor prevents infiltration and cerebrospinal fluid dissemination in malignant glioma: an experimental study.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cadherins; Cell Line; Enzyme Inhibitors; ErbB Receptors; Glioma; Male; Neoplasms, Experimental; Quinazolines; Rats; Rats, Sprague-Dawley; Tyrphostins; Up-Regulation | 2011 |
Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Survival; Dacarbazine; ErbB Receptors; Glioma; Humans; Immunoblotting; Mice; Mice, Nude; Quinazolines; Radiation Tolerance; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A; X-Rays | 2011 |
Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cyclic AMP-Dependent Protein Kinases; Gefitinib; Glioma; Humans; Immunoprecipitation; Membrane Potential, Mitochondrial; Phosphorylation; Quinazolines; RNA, Small Interfering; Transfection | 2011 |
MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bcl-2-Like Protein 11; Beclin-1; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Glioma; Heterocyclic Compounds, 3-Ring; Humans; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; RNA, Small Interfering | 2012 |
EGFR inhibitor enhances cisplatin sensitivity of human glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Glioma; Humans; Protein Tyrosine Phosphatases; Quinazolines; Tyrphostins | 2011 |
Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression; Glioma; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Survival Rate; Tumor Cells, Cultured; Young Adult | 2012 |
Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.
Topics: Angiogenesis Inhibitors; Animals; Benzimidazoles; Biomarkers, Tumor; Contrast Media; Dextrans; Fluorescent Dyes; Glioma; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Nitroimidazoles; Quinazolines; Radiation-Sensitizing Agents; Rats; Rats, Nude; Tumor Cells, Cultured | 2012 |
Aurora kinase B/C inhibition impairs malignant glioma growth in vivo.
Topics: Animals; Apoptosis; Astrocytes; Aurora Kinase B; Aurora Kinase C; Aurora Kinases; Blotting, Western; Cell Proliferation; Cells, Cultured; Fluorescent Antibody Technique; Forkhead Transcription Factors; Glioma; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Protein Serine-Threonine Kinases; Quinazolines; RNA, Messenger | 2012 |
Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; DNA Breaks, Double-Stranded; DNA-Activated Protein Kinase; ErbB Receptors; Gefitinib; Glioma; Histones; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Neuroglia; Phosphorylation; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Stem Cell Assay | 2012 |
Occupy EGFR.
Topics: Animals; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Kinetics; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lapatinib; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Synthesis and in vitro evaluation of [18F](R)-FEPAQ: a potential PET ligand for VEGFR2.
Topics: Brain; Drug Evaluation, Preclinical; Fluorine Radioisotopes; Glioma; Humans; Ligands; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Stereoisomerism; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Blockade of EGFR signaling promotes glioma stem-like cell invasiveness by abolishing ID3-mediated inhibition of p27(KIP1) and MMP3 expression.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Glioma; Humans; Inhibitor of Differentiation Proteins; Matrix Metalloproteinase 3; Mice; Neoplasm Proteins; Neoplastic Stem Cells; Quinazolines; Signal Transduction; Tyrphostins | 2013 |
Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Coumarins; Endocytosis; Fluorescent Antibody Technique; Glioma; Humans; Imaging, Three-Dimensional; In Situ Nick-End Labeling; Lapatinib; Lipoproteins; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Nanoparticles; Osteonectin; Quinazolines; Receptor, ErbB-2; Subcellular Fractions; Xenograft Model Antitumor Assays | 2012 |
Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Drug Synergism; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Gene expression changes associated with erlotinib response in glioma cell lines.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cluster Analysis; Cyclin-Dependent Kinase Inhibitor p16; DNA-Binding Proteins; Endonucleases; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Humans; Inhibitor of Apoptosis Proteins; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Survivin; Transcription Factors | 2013 |
Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.
Topics: Astatine; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioma; Humans; Metabolic Clearance Rate; Protein-Tyrosine Kinases; Quinazolines; Radioisotopes; Radiopharmaceuticals | 2003 |
Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Glioma; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor; Trans-Activators; Tumor Suppressor Proteins | 2003 |
Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Survival; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Glioma; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrphostins | 2003 |
Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Division; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Glioma; Humans; Mice; Mice, Inbred BALB C; Naphthalenes; NIH 3T3 Cells; Oncogene Proteins v-erbB; Phosphoinositide-3 Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Signal Transduction; Transduction, Genetic; Xenograft Model Antitumor Assays | 2003 |
Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death.
Topics: Adenosine Triphosphate; Cell Death; Cell Hypoxia; DNA Replication; ErbB Receptors; Glioma; Glucose; Humans; Membrane Potentials; Mitochondria; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction; Tyrphostins | 2004 |
INK4a/Arf is required for suppression of EGFR/DeltaEGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma.
Topics: Animals; Astrocytes; Cyclin-Dependent Kinase Inhibitor p16; Enzyme Activation; ErbB Receptors; Glioma; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Tyrphostins | 2004 |
The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Division; Disease Models, Animal; Enzyme Inhibitors; Glioma; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Rats | 2004 |
Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis.
Topics: Apoptosis; Brain Neoplasms; Caspase 8; Caspases; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Fas Ligand Protein; Glioma; Humans; Membrane Glycoproteins; Quinazolines; Receptor, IGF Type 1; Ribosomal Protein S6; Signal Transduction; Tumor Suppressor Protein p53; Tyrphostins | 2004 |
EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.
Topics: Adenosine Triphosphate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Calcium; Calcium Signaling; Carcinoma, Squamous Cell; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Protein Kinase Inhibitors; Quinazolines; Receptors, Purinergic; Tumor Cells, Cultured | 2004 |
EGFR tyrosine kinase domain mutations in human gliomas.
Topics: Astrocytoma; Brain Neoplasms; Carcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Testing; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Oligodendroglioma; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines | 2005 |
Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Patient Selection; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2005 |
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Ependymoma; ErbB Receptors; Glioma; Humans; Immunohistochemistry; Ki-67 Antigen; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2005 |
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Caspase 3; Caspases; Cell Proliferation; Drug Combinations; Enzyme Activation; ErbB Receptors; Fibroblasts; G1 Phase; Gefitinib; Glioma; Humans; Lactams, Macrocyclic; Lung; Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Quinazolines; Rifabutin; Signal Transduction; Tumor Stem Cell Assay | 2006 |
Evolution of management strategies for cerebral gliomas: the effects of science and technology.
Topics: Antibiotics, Antineoplastic; Brain Neoplasms; DNA Repair; DNA-Binding Proteins; Doxorubicin; Endonucleases; Erlotinib Hydrochloride; Gene Silencing; Genes, erbB-1; Genome, Human; Glioma; Humans; Protein Kinase Inhibitors; Quinazolines; Xeroderma Pigmentosum Group D Protein | 2005 |
Perspectives in central nervous system malignancies.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Glioma; Humans; Indoles; Protein Kinase C; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; TOR Serine-Threonine Kinases | 2006 |
Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors.
Topics: Animals; Cell Line, Tumor; Drug Evaluation, Preclinical; ErbB Receptors; Fluorine Radioisotopes; Gene Expression Regulation, Neoplastic; Glioma; Humans; Metabolic Clearance Rate; Mice; Mice, Nude; Molecular Probe Techniques; Organ Specificity; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Tissue Distribution | 2007 |
Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Chromones; Enzyme Inhibitors; Gene Expression; Glioma; Gliosarcoma; Humans; Hydroxamic Acids; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microscopy, Fluorescence; Mitogen-Activated Protein Kinase 1; Morpholines; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Transfection; Tyrphostins | 2007 |
Indomethacin stimulates activity and expression of ecto-5'-nucleotidase/CD73 in glioma cell lines.
Topics: 5'-Nucleotidase; Actins; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Tumor; Cell Proliferation; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Enzyme Activation; Flow Cytometry; Gene Expression Regulation, Enzymologic; Glioma; Humans; Indomethacin; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Theophylline; Time Factors; Triazoles; Xanthines | 2007 |
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Furans; Glioma; Humans; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; PTEN Phosphohydrolase; Pyridines; Pyrimidines; Quinazolines; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Cells, Cultured | 2007 |
Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; DNA Fragmentation; Drug Administration Schedule; Endothelium, Vascular; ErbB Receptors; Gefitinib; Glioma; Humans; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Receptor, ErbB-2 | 2007 |
Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Blood-Brain Barrier; Brain Neoplasms; Contrast Media; Dextrans; Ferrosoferric Oxide; Gadolinium DTPA; Glioma; Immunohistochemistry; Iron; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Oxides; Piperidines; Predictive Value of Tests; Quinazolines; Transplantation, Heterologous | 2008 |
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aza Compounds; Brain Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mutation; Promoter Regions, Genetic; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA Interference; RNA, Messenger; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Suppressor Protein p53; Up-Regulation; Valine | 2008 |
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Glioma; Neoplasm Transplantation; Piperidines; Quinazolines; Rats; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2008 |
EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Enzyme Activation; Ependymoma; ErbB Receptors; Female; Flow Cytometry; G1 Phase; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Situ Nick-End Labeling; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2008 |
Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors.
Topics: Benzylidene Compounds; Cell Division; Enzyme Inhibitors; ErbB Receptors; Gene Amplification; Glioma; Humans; Mutation; Nitriles; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured; Tyrphostins | 1996 |
CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Brain Neoplasms; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cell Survival; Coumarins; Cycloheximide; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Fas Ligand Protein; Fluorescent Dyes; Gene Expression Regulation, Neoplastic; Glioma; Humans; Membrane Glycoproteins; Oligopeptides; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Serpins; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tyrphostins; Viral Proteins | 2002 |
TGF-alpha-driven tumor growth is inhibited by an EGF receptor tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Blotting, Northern; Blotting, Western; Cell Division; DNA, Complementary; Enzyme Inhibitors; ErbB Receptors; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; RNA; RNA, Messenger; Tetracycline; Time Factors; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured; Tyrosine; Tyrphostins | 2002 |
Phase II study of trimetrexate in recurrent anaplastic glioma. National Cancer Institute of Canada Clinical Trials Group Study.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Drug Evaluation; Female; Glioma; Humans; Injections, Intravenous; Male; Middle Aged; Quinazolines; Trimetrexate | 1990 |